Table 2.
Participant characteristics following each treatment.
| Participants | ||
|---|---|---|
| Placebo | G. pentaphyllum | |
| Age (years) | 23.3 ± 1.1 | |
| Height (cm) | 174.4 ± 1.6 | |
| Body Mass (kg) | 69.0 ± 1.9 | 68.7 ± 1.8 |
| BMI (kg/m2) | 22.6 ± 0.5 | 22.6 ± 0.5 |
| VO2 peak (mL·kg−1·min−1) | 40.8 ± 1.7 | |
| Peak power (Watts) | 214.3 ± 11.3 | |
| TtE power output (Watts) | 161.2 ± 9.2 | 160.9 ± 9.3 |
| SS power output (Watts) | 103.6 ± 6.5 | 105.2 ± 7.2 |
| Plasma fasting glucose (mmol/L) | 5.15 ± 0.11 | 4.86 ± 0.07 * |
| Total cholesterol (mmol/L) | 3.71 ± 0.18 | 3.76 ± 0.14 |
| HDL (mmol/L) | 1.24 ± 0.04 | 1.3 ± 0.05 * |
| LDL (mmol/L) | 2.05 ± 0.18 | 1.98 ± 0.12 |
| LDL/HDL | 1.69 ± 0.16 | 1.56 ± 0.13 |
| Total cholesterol/HDLC | 3.04 ± 0.16 | 2.90 ± 0.16 |
| Total triglycerides (mmol/L) | 0.98 ± 0.11 | 1.04 ± 0.16 |
| Adiponectin (µg/mL) | 7.09 ± 0.42 | 8.55 ± 1.02 |
| Leptin (ng/mL) | 1.31 ± 0.07 | 1.15 ± 0.07 * |
LDL: low-density lipoprotein–cholesterol; HDL: high-density lipoprotein–cholesterol; TtE: time to exhaustion test; SS: steady state. Values are expressed as means ± SEM. n = 16. * p < 0.05 compared to placebo.